



Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

Yee Kit Tai^{1,2}, Karen Ka Wing Chan^{1,2}, Charlene Hui Hua Fong^{1,2}, Sharanya Ramanan^{1,2}, Jasmine Lye Yee Yap^{1,2}, Jocelyn Naixin Yin^{1,2}, Yun Sheng Yip³, Wei Ren Tan³, Angele Pei Fern Koh⁴, Nguan Soon Tan^{3,5}, Ching Wan Chan^{6,7}, Ruby Yun Ju Huang^{4,8}, Jing Ze Li¹, Jürg Fröhlich^{1,9,10} and Alfredo Franco-Obregón^{1,2,11,12,13,14*}

OPEN ACCESS

Edited and reviewed by:

Tarik Smani,
Sevilla University, Spain

*Correspondence:

Alfredo Franco-Obregón
suraf@nus.edu.sg

Specialty section:

This article was submitted to
Cancer Molecular Targets
and Therapeutics,
a section of the journal
Frontiers in Oncology

Received: 09 March 2022

Accepted: 31 March 2022

Published: 20 April 2022

Citation:

Tai YK, Chan KKW, Fong CHH,
Ramanan S, Yap JLY, Yin JN,
Yip YS, Tan WR, Koh APF, Tan NS,
Chan CW, Huang RYJ, Li JZ, Fröhlich J
and Franco-Obregón A (2022)
Corrigendum: Modulated TRPC1
Expression Predicts Sensitivity of Breast
Cancer to Doxorubicin and Magnetic
Field Therapy: Segue Towards a
Precision Medicine Approach.
Front. Oncol. 12:892408.
doi: 10.3389/fonc.2022.892408

¹ Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

² Biolumic Currents Electromagnetic Pulsing Systems Laboratory (BICEPS), National University of Singapore, Singapore, Singapore,

³ Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore,

⁴ Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore, ⁵ School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore, ⁶ Division of General Surgery (Breast Surgery), Department of Surgery, National University Hospital, Singapore, Singapore, ⁷ Division of Surgical Oncology, National University Cancer Institute, Singapore, Singapore, ⁸ Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁹ Fields at Work GmbH, Zürich, Switzerland, ¹⁰ Institute of Electromagnetic Fields, ETH Zürich (Swiss Federal Institute of Technology in Zürich), Zürich, Switzerland, ¹¹ Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore, Singapore, ¹² Competence Center for Applied Biotechnology and Molecular Medicine, University of Zürich, Zürich, Switzerland, ¹³ Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ¹⁴ Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Keywords: breast cancer, PEMFs, EMT, patient-derived xenograft, chorioallantoic membrane, doxorubicin, TRPC1, chemotherapy

A Corrigendum on:

Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

By Tai YK, Ramanan S, Chan KKW, Yap JLY, Fong CHH, Yin JN, Tan WR, Koh APF, Tan NS, Yip YS, Chan CW, Huang RYJ, Li JZ, Fröhlich J and Franco-Obregón A (2022) *Front. Oncol.* 11:783803.
doi: 10.3389/fonc.2021.783803

In the original article, there was a nonconsequential error in **Figure 1** as published. A file concatenation error occurred within the FACS analysis software that implicated the scatter dot-plots shown in **Figure 1C**. The corrected **Figure 1** appears below.




FIGURE 1 | PEMFs synergize with DOX to inhibit tumor growth in vivo. **(A)** Schematic of PEMF and DOX exposure regimes used on mice hosting patient-derived tumor xenografts. Implanted tumors were allowed to grow for 3 weeks before the initiation of DOX (20 mg/kg) and/or PEMF treatments. Tumor volumes were measured each week while apoptotic cell determination was performed at the end of the study. Each data point represents the mean values from 5 experimental runs derived from the tumors obtained from 5 patients, each of which was equally divided amongst the 5 treatment groups. **(B)** Changes in tumor volume (mm^3) for 5 weeks. **(C)** Representative scatter dot-plots showing cell populations from dissociated tumors based on Annexin V and propidium iodide staining. **(D)** Quantification of apoptotic cell percentages obtained using flow cytometry. $*p < 0.05$, $**p < 0.01$, and $^{\#}p < 0.0001$. Error bars represent the standard error of the mean.

The associated corrected values that appear in the text of the **Results** under the subheading “*PEMF and Doxorubicin Treatments Act Synergistically to Impair Breast Cancer Tumor Growth In Vivo*”, paragraph one, should read “Moreover, the incidence of apoptotic cells increased by +0.55%, +10.2%, and +18% in tumors isolated from control, PEMF-exposed and DOX-treated mice, respectively (**Figures 1C, D**)”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.